Subscribe Us

header ads

Recents

header ads

Viral Vectors & Plasmid DNA Manufacturing Market Size, Growth, Demands Outlook and Forecasts to 2030

Precedence Research - October 11, 2022

 According to the research report, the global viral vectors & plasmid DNA manufacturing market size is expected to touch USD 4286.79  Billion by 2030, from USD 1060.73 Billion in 2021, growing with a significant CAGR of 2% from 2022 to 2030. 

Viral Vectors and Plasmid DNA Manufacturing Market Size 2021-2030

The viral vectors & plasmid DNA manufacturing market report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global viral vectors & plasmid DNA manufacturing market in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global viral vectors & plasmid DNA manufacturing market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global viral vectors & plasmid DNA manufacturing market during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link https://www.precedenceresearch.com/sample/1012

 Scope of the Viral Vectors & Plasmid DNA Manufacturing Market

Report HighlightsDetails
Market Size by 2030USD 4286.79 million
Growth RateCAGR of 16.8% From 2022 to 2030
Base Year2021
Historic data2017 to 2021
Forecast Period2022 to 2030
Segments CoveredVector Type, Application, Workflow, End-User, Disease
Regional ScopeAsia Pacific, North America, Europe, Latin America, Middle East and Africa

This study covers a detailed segmentation of the global viral vectors & plasmid DNA manufacturing market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global viral vectors & plasmid DNA manufacturing market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • Novasep
  • Aldevron
  • MerckWaismanBiomanufacturing
  • Creative Biogene
  • The Cell and Gene Therapy Catapult
  • Cobra Biologics
  • uniQure N.V.
  • Addgene
  • FUJIFILM Holdings Corporation
  • Oxford Biomedicaplc
  • Takara Bio Inc.

Market Segmentation

 By Vector Type

  • Adenovirus
  • Plasmid DNA
  • Lentivirus
  • Retrovirus
  • AAV
  • Others

By Application

  • Gene Therapy
  • Antisense &RNAi
  • Cell Therapy
  • Vaccinology

By Workflow

  • Upstream Processing
    • Vector Recovery/Harvesting
    • Vector Amplification & Expansion
  • Downstream Processing
    • Fill-finish
    • Purification

By End-User

  • Biopharmaceutical and Pharmaceutical Companies
  • Research Institutes

By Disease

  • Genetic Disorders
  • Cancer
  • Infectious Diseases
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Research Methodology

The research methodology adopted by analysts for compiling the global viral vectors & plasmid DNA manufacturing market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global viral vectors & plasmid DNA manufacturing market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type, 2022-2030
7.1.1. Adenovirus
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Lentivirus
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Retrovirus
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. AAV
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type, 2022-2030
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Antisense &RNAi
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Cell Therapy
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Vaccinology
8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type, 2022-2030
9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Downstream Processing (Fill-finish, Purification)
9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type

10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type, 2022-2030
10.1.1. Biopharmaceutical and Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease

11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease, 2022-2030
11.1.1. Genetic Disorders
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Cancer
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue and Forecast, by Vector (2017-2030)
12.1.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.4. Market Revenue and Forecast, by End-User (2017-2030)
12.1.5. Market Revenue and Forecast, by Disease (2017-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.1.7. Market Revenue and Forecast, by Disease (2017-2030)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, by Vector (2017-2030)
12.1.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.1.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.1.9. Market Revenue and Forecast, by Disease (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.5. Market Revenue and Forecast, by Disease (2017-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.7. Market Revenue and Forecast, by End-User (2017-2030)
12.2.8. Market Revenue and Forecast, by Disease (2017-2030)
12.2.8.1. Market Revenue and Forecast, by Raw Material (2017-2030)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.9.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.9.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.10. Market Revenue and Forecast, by End-User (2017-2030)
12.2.11. Market Revenue and Forecast, by Disease (2017-2030)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.12.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.12.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.12.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.13. Market Revenue and Forecast, by Disease (2017-2030)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, by Vector (2017-2030)
12.2.14.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.14.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.2.14.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.15. Market Revenue and Forecast, by Disease (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.5. Market Revenue and Forecast, by Disease (2017-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.7. Market Revenue and Forecast, by Disease (2017-2030)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.9. Market Revenue and Forecast, by Disease (2017-2030)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.10.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.10.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.10.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.10.5. Market Revenue and Forecast, by Disease (2017-2030)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, by Vector (2017-2030)
12.3.11.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.11.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.3.11.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.11.5. Market Revenue and Forecast, by Disease (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.5. Market Revenue and Forecast, by Disease (2017-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.7. Market Revenue and Forecast, by Disease (2017-2030)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.9. Market Revenue and Forecast, by Disease (2017-2030)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.10.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.10.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.10.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.10.5. Market Revenue and Forecast, by Disease (2017-2030)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, by Vector (2017-2030)
12.4.11.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.11.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.4.11.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.11.5. Market Revenue and Forecast, by Disease (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Vector (2017-2030)
12.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5.5. Market Revenue and Forecast, by Disease (2017-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Vector (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5.7. Market Revenue and Forecast, by Disease (2017-2030)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, by Vector (2017-2030)
12.5.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.8.3. Market Revenue and Forecast, by Workflow (2017-2030)
12.5.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5.8.5. Market Revenue and Forecast, by Disease (2017-2030)

Chapter 13. Company Profiles

13.1. Novasep
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Aldevron
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck Waisman Biomanufacturing
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Creative Biogene
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Cell and Gene Therapy Catapult
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Cobra Biologics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. uniQure N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Addgene
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FUJIFILM Holdings Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Oxford Biomedicaplc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. Takara Bio Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

Tags:

Post a Comment

0 Comments